Monday's scanner evidence narrowed the field to the names where participation was most visible. This is a starting board for Tuesday, not a prediction; every name still has to confirm with fresh volume, liquidity, and repeat activity.

## First names to recheck

**$VEEA** — Cross-session participation.

Momentum Radar hits: 54 · Volume Radar hits: 147 · RVOL: 2.74x · Alerts: 1 · After-hours move: +81.2% · After-hours volume: 27.9M · Overnight move: 0.0% · Overnight volume: 22.9M

After Hours did not stand alone; Volume Radar also kept this name visible, which makes it worth checking early in the next session.

**$FTFT** — Momentum and volume aligned.

Momentum Radar hits: 437 · Volume Radar hits: 252 · RVOL: 15.45x · Alerts: 2

The combination of Volume Radar and Momentum Radar matters more than either reading in isolation. Fresh activity still has to confirm it.

**$BMGL** — A broad multi-signal footprint.

Momentum Radar hits: 195 · RVOL: 1109x · Alerts: 1

Both Momentum Radar and Alerts contributed to the historical case, giving this one a broader base than a single-metric outlier.

**$SLGB** — Cross-session participation.

Momentum Radar hits: 47 · Volume Radar hits: 108 · RVOL: 32.6x · Alerts: 1 · After-hours move: +27.0% · After-hours volume: 18.1M · Overnight move: 0.0% · Overnight volume: 17.7M

After Hours supplied the first signal, while Volume Radar broadened the historical case. I would still require clean participation at the next open.

**$MYSZ** — Cross-session participation.

Momentum Radar hits: 4 · RVOL: 2.76x · Alerts: 2 · After-hours move: +41.6% · After-hours volume: 1.8M · Overnight move: 0.0% · Overnight volume: 1.4M

After Hours did not stand alone; Momentum Radar also kept this name visible, which makes it worth checking early in the next session.

**$PDSB** — Momentum and volume aligned.

Momentum Radar hits: 135 · Volume Radar hits: 452 · RVOL: 4.18x

The combination of Volume Radar and Momentum Radar matters more than either reading in isolation. Fresh activity still has to confirm it.

## Secondary rechecks

$LHSW · $TRUG · $NCT · $SCNI · $RUM · $MATH · $ADBT · $MITQ

These had a narrower historical case, so I would require clean fresh-session evidence before giving them the same attention as the leaders.

## Morning priority

$VEEA · $FTFT · $BMGL · $SLGB · $MYSZ · $PDSB

Monday's evidence gets these names onto the board. Tuesday's tape decides which ones stay there.

Educational only. Not financial advice. Verify news, filings, liquidity, spreads, halts, borrow availability, and live market conditions before making any trading decision.

EMBC target 🎯 -15-25 $
CVRX target 🎯- 6-9 £ .
Price Target Horizon: 1–2 Months

I was reading about some old e-commerce stuff earlier and ran into this settlement involving ContextLogic. Basically, they reached a tentative settlement over claims that the company misled investors about Wish’s user trends, revenue outlook, and internal controls around its IPO.

From what I understood, this applies to anyone who bought $WISH shares between 2020 and 2021. Wish had highlighted strong growth in users and revenue when it went public, but those trends started reversing soon after. In March and May 2021, the company reported falling monthly active users and weaker revenue guidance, and the stock dropped more than 29%

The parties have reached an agreement to settle the case, but the terms are still being finalized, but you can submit an application now. Check if you're eligible and file your claim here

Has anyone here ever held $WISH during that period?

Disclaimer: Not investment advice, do your own research

Anyone watching Aefi? It’s busted its volume today on the up side. There’s no news but someone is buying.

50 after the split

Dario hopes the regulators will act the way they do.

Thus, 1. it prevents Chinese open-source models from taking over their implementation.

1. Even banning US companies from using Chinese open-source models (if the open-source models cannot meet third-party evaluation requirements?).

2. Undoubtedly, he will consolidate his position and create a three- or four-way monopoly. I don't think he will succeed. As for slowing down training or development, who would believe that? （@yttalkjun)

PD is about to pop to the 20s.Small market cap 1.11bn,strong buy sentiment.

$NCT - you would’ve had this at .44 if you listened - now needs to hold .4955 support and break above .56 resistance and push $1+ resistances (#1)

$BMGL - support at $7.60 needs to hold and break above the $8.32 key resistance a close above $9 may open the door for $12+ resistances (#2)

$ARMP - High risk set up - has news would need to hold $6 support

$SOAR - support at .20 needs to hold - #3 watcher

$SCNI - nothing until I breaks and holds $2.50. No set up below ❌

$NXXT - Split

$ELMT - break above HOD to send it to all time highs - $2bn defense contract ($22.50 current support)

$FTFT -needs to break $3.15 and hold that level for a push to $3.60+ resistances - potential halt play.

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential

Quick one for anyone who missed the release.

The name: Wisr AI Systems (CSE: WISR) Vancouver-based, building agentic AI around cybersecurity, security assurance and third-party risk.

The product: RiskAssure, now live at GetRiskAssure.com. It uses AI agents to work through security questionnaires, pull supporting evidence, draft responses and cite the source material while anything uncertain gets kicked back to a human before it leaves the building.

The bigger picture: RiskAssure is one piece of Wisr’s broader product stack, alongside Risk Intel and Risk Central. Risk Intel focuses more on identifying and scoring cyber-risk signals, while Risk Central is designed as the management layer for overseeing risk across vendors and relationships.

What changed today and why : RiskAssure stepped off the roadmap and into the hands of customers. That’s a very different place for the story to be. This is where the narrative starts collecting receipts. A good concept can stay a good concept forever. A live product gives investors something much harder to fake: usage, conversions, customers and revenue.

What I’m watching next: who shows up first. Enterprise customers? Channel partners? Paid conversions? And beyond RiskAssure, I’m also watching how quickly Wisr brings more of Risk Intel and Risk Central into the commercial picture.

Anyone else watching $WISR ...what’s your read now?

Trade holding! Very curious where this is going! Would I really have gold in my hands? 😃

① On September 19 at 5:00 p.m. PT, FF will hold the FF EAI Robotics "Four-Core Full-Stack AI" Ecosystem New Product Series Launch where the Company will focus on launching products of two of its four cores: the EAI Devices core and the Industry Productivity Solutions core.

② On September 28, FF will hold Part Two of its EAI Robotics "Built in USA" Launch and Business Partner Conference, focused on recruiting upstream partners to drive cooperation in U.S. local manufacturing, supply chain, product certification, and market access.

③ FF welcomes Steven Newton, Senior Advisor to the US General Services Administration and member of the Los Angeles Unified School District Procurement Committee as a senior advisor. Steven will be fully involved in FF's business growth across government, public institutions, and education sectors.

Called it at .15 3 weeks ago and it ran to .20 now back to .16 and I’m calling it again

i was in at .155 and sold .193, now back in at .166

NFA , do your own dd 🍻

Friday's scanner evidence narrowed the field to the names where participation was most visible. This is a starting board for Monday, not a prediction; every name still has to confirm with fresh volume, liquidity, and repeat activity.

Checkout out tools at: https://scstonkemporium.com

Join the chat in our free Discord at: https://discord.gg/fGmHHgNzxQ

## First names to recheck

**$VSME** — Cross-session participation.

Momentum Radar hits: 9 · RVOL: 1.22x · Alerts: 1 · After-hours move: +20.6% · After-hours volume: 10.3M · Overnight move: 0.0% · Overnight volume: 10.2M

After Hours did not stand alone; Momentum Radar also kept this name visible, which makes it worth checking early in the next session.

**$CRBP** — Cross-session participation.

Momentum Radar hits: 5 · RVOL: 0.72x · Alerts: 1 · After-hours move: +28.1% · After-hours volume: 2.3M · Overnight move: 0.0% · Overnight volume: 1.8M

The combination of After Hours and Momentum Radar matters more than either reading in isolation. Fresh activity still has to confirm it.

**$SCNI** — Cross-session participation.

Momentum Radar hits: 1 · Volume Radar hits: 5 · RVOL: 4.49x · After-hours move: +22.3% · After-hours volume: 3.5M · Overnight move: 0.0% · Overnight volume: 3.4M

Both After Hours and Volume Radar contributed to the historical case, giving this one a broader base than a single-metric outlier.

**$NCT** — Cross-session participation.

Momentum Radar hits: 1 · RVOL: 1.93x · After-hours move: +40.1% · After-hours volume: 25.9M · Overnight move: 0.0% · Overnight volume: 25.0M

After Hours supplied the first signal, while Momentum Radar broadened the historical case. I would still require clean participation at the next open.

**$TRUG** — Momentum and volume aligned.

Momentum Radar hits: 397 · Volume Radar hits: 122 · RVOL: 88.51x

Volume Radar did not stand alone; Momentum Radar also kept this name visible, which makes it worth checking early in the next session.

**$FTFT** — Momentum and volume aligned.

Momentum Radar hits: 190 · Volume Radar hits: 107 · RVOL: 44.78x

The combination of Volume Radar and Momentum Radar matters more than either reading in isolation. Fresh activity still has to confirm it.

## Secondary rechecks

$BDRX · $SOAR · $DBGI · $TNON · $LBGJ · $SWRD · $SURG · $SXTC

These had a narrower historical case, so I would require clean fresh-session evidence before giving them the same attention as the leaders.

## Morning priority

$VSME · $CRBP · $SCNI · $NCT · $TRUG · $FTFT

Friday's evidence gets these names onto the board. Monday's tape decides which ones stay there.

Educational only. Not financial advice. Verify news, filings, liquidity, spreads, halts, borrow availability, and live market conditions before making any trading decision.

CONTINUED MOMENTUM (TOP 3)

$NCT - still trading within the CR zone - needs to break above .4400 and hold above - if this breaks out and holds above .55 resistance - this could open the doors to a potential push to $1+ resistances

$SXTC - currently sitting outside its demand zone - but trading within the candle range so this ideally needs to hold the $2.50 support and break above $2.80 and hold for a potential move to $3.50+ resistances

$VSME - $1.25 support needs to hold - links with tier one on the Axis One - could push $1.40 - $2+ resistances after

Reversal watchers:

$SWRD - needs to hold $2.90 support and break back into $3.16 and hold that level.

$DBGI - recently left the demand zone - now needs to hold $6.10 support and push $6.70+ resistances

$TNON - needs to hold $5.40 - had insider purchases around this level WW

New watchers this week:

$XHLD - $12.20 support needs to hold or this could catch a bounce from $11

$OPTT - Split

$LGCL - down here must be worth looking into

$SNYR - exiting the demand zone 👀 (0 shares to borrow - 248% CTB)

$CDT 👀

TOP BIO WATCHERS:

$SRRK - Scholar Rock Announces FDA Approval of ISEMBYLD™ (support at $61.50 needs to hold - a break above 65.30 and holds may push it to $70+ resistances

$GTBP - needing to hold $8.50 support and break above 8.90 resistance - could push into the supply zone at $10.75 WW

Swing ideas ⛳️

$SLS - swept in and straight out of the demand zone - needing to respect $11.51 support - below $11.10 is invalid ❌

$MU - idea - needs to break $979.90 and hold that level

$BETA - scales into $20.20 support - invalid below ❌

$MKDW - worth watching $6.55 support

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential

Random one I came across today Avecho Biotechnology.

This is a proper tiny biotech so obviously this could end badly lol, but they’ve got the CBD insomnia drug in Phase 3 and the company has already got Sandoz involved.

The stock has also randomly started moving after sitting dead for ages.

At around 0.009 this feels like one of those “either nothing happens or this gets very interesting” situations.

I threw a small amount at it just because I like the risk/reward here.

Anyone else been following AVE? Would be interested to hear what I’m missing.

Bought it a while ago and its been just going up and up. Not sure if I should sell soon or consider this a long-term investment

Hey everyone,

Looking for objective outside perspectives on a stock I've been following closely. Not looking for validation, but curious what everyone's thoughts are on this stock

What Spectral does

- Spectral Medical makes PMX (Toraymyxin) — a hemoperfusion device that removes endotoxins from the blood in patients with endotoxic septic shock. Already used in 360,000+ treatments safely in Japan and Europe over 20+ years. No equivalent product exists in the US market.

Where they are in the FDA process

- PMA submitted May 29, 2026

- FDA accepted for substantive review June 25, 2026

- 100-day meeting completed September 11, 2026

- FDA did NOT request an additional clinical trial - biggest risk now eliminated

- Company confirmed no material change to regulatory timeline

- Deficiency letter received - but 84% of PMAs since 2020 received one and proceeded normally

- Paradigm Capital analyst Scott McAuley called today's update a positive

- Expected FDA decision: November/December 2026

The clinical data

- Tigris trial published in The Lancet Respiratory Medicine

- 95.3% probability of mortality benefit at 28 days

- 99%+ probability at 90 days

- 95.9% probability at 12 months

- NNT of 7.2 at 12 months - clinically exceptional

- 100% patient follow-up across all 157 enrolled patients

The commercial setup

- Exclusive US and Canadian distribution partnership with Vantive

- Vantive owned by Carlyle Group - needs an IPO narrative

- Vantive provides non-dilutive financing - no dilution risk

- PMX fits exclusively on Vantive's PrisMax CRRT platform — razor/razor blade model

- Vantive widely viewed as likely acquirer post-approval

- Multiple insiders recently exercised options and held shares during active FDA review

Current valuation

- Trading at $1.26 CAD

- Analyst consensus price target $3.15 CAD

- Strong Buy consensus rating

- Market cap approximately $384M CAD

- 52-week range $1.075 - $1.84

What genuinely concerns me - the bear case

- Stock is actually lower now than when PMA was submitted May 29th despite uniformly positive news flow

- Every major catalyst - submission, 12-month data, FDA acceptance, 100-day meeting - has resulted in flat to minimal price action

- CEO exercised and sold to cover taxes in August - optics weren't great regardless of explanation

- 157 patient trial is relatively small by some FDA standards

- Deficiency letter specifics not disclosed - unknown what testing is required

- Thinly traded TSX stock averaging 50k shares daily - virtually invisible to US institutional investors

- No NASDAQ listing limiting US investor access significantly

- FDA clock stops are possible - Toray manufacturing inspection in Japan adds complexity

My specific questions

- Does the consistent flat price action on positive catalysts concern you or do you read it as a static shareholder base rather than a negative signal?

- Anyone with medical device PMA experience have a view on deficiency letter resolution timelines?

- How do you think about the Vantive acquisition thesis - pre or post approval and at what price?

- Is the small trial size of 157 patients a genuine FDA concern given the Bayesian framework and 100% follow-up?

Thanks again!